Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application lacosamide oral solution USP, 10mg/mLs. Aurobindo Pharma’s lacosamide oral solution, are an AB-rated generic equivalent to the reference listed drug (RLD), VIMPAT Oral Solution manufactured by UCB.
Lacosamide oral solution are indicated in patients 17 years and older with partial-onset seizures as monotherapy or adjunctive therapy.
Lacosamide oral solution has an estimated market size of US $70.4 Million for the twelve months ending Nov 2023, as per IQVIA.
